F
Frederick Klauschen
Researcher at Humboldt University of Berlin
Publications - 238
Citations - 17312
Frederick Klauschen is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 170 publications receiving 12451 citations. Previous affiliations of Frederick Klauschen include Charité & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Association of an APOBEC mutational signature, mutational load, and BRCAness with inflammation and PD-L1 expression in HNSCC.
Damian T. Rieke,Clemens Messerschmidt,Sebastian Ochsenreither,Konrad Klinghammer,Inge Tinhofer,Korinna Jöhrens,Frederick Klauschen,Dieter Beule,Ulrich Keilholz +8 more
TL;DR: This study analyzed mutational signatures to identify recurrent mutational patterns associated with inflammation in inflamed and non-inflamed tumors and found an APOBEC-associated tCw (thymine – cytosine – adenine/thymine) mutational signature was significantlyassociated with inflammation.
Journal ArticleDOI
Somatic genome alterations in relation to age in lung squamous cell carcinoma.
TL;DR: Signs are provided of age-dependent differences in mutational backgrounds (SNPs and CNVs) as well as epigenetic patterns that might be relevant for age adjusted treatment approaches that may contribute to the higher mutational burden of younger patients.
Journal ArticleDOI
Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature
Sandra Liebs,Sandra Liebs,Anika Nonnenmacher,Frederick Klauschen,Frederick Klauschen,Ulrich Keilholz,Loredana Vecchione +6 more
TL;DR: This case demonstrates the utility of liquid biopsy to identify the predominant tumour burden in patients with multiple primary cancers, based on the detection of the tumour-associated gene mutation in the plasma.
Journal ArticleDOI
Diagnostic Accuracy of Magnetic Resonance Enterography for the Evaluation of Active and Fibrotic Inflammation in Crohn’s Disease
Florian N. Loch,Carsten Kamphues,Katharina Beyer,Frederick Klauschen,Christian Schineis,Benjamin Weixler,Johannes C. Lauscher,Marc Dorenbeck,Christiane Bayerl,Rolf Reiter +9 more
TL;DR: Findings indicate that the MRE-based AIS allows a better determination of the inflammatory stage of terminal ileal CD, which facilitates the decision to perform surgery.
Journal ArticleDOI
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
Ramona Erber,Miriam Angeloni,Robert Stöhr,Michael P. Lux,D. Ulbrich-Gebauer,E Pelz,Agnes Bankfalvi,Kurt Werner Schmid,Robert Fh Walter,Martina Vetter,Christoph Thomssen,Doris Mayr,Frederick Klauschen,Peter Sinn,Karl Sotlar,K Stering,Albrecht Stenzinger,Marius Wunderle,Peter A. Fasching,Matthias W. Beckmann,Oliver Hoffmann,Rainer Kimmig,Nadia Harbeck,Rachel Wuerstlein,Fulvia Ferrazzi,Arndt Hartmann +25 more
TL;DR: In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests using the PAM50-based multigenes expression test Prosigna® in a prospective multicentric study.